Business Context and Reporting Period
Company: Exponent, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: April 4, 2003
Business Overview: Exponent is a science and engineering consulting firm providing solutions to complex problems across more than 70 technical disciplines. The company operates two primary segments: Environmental and Health, and Other Scientific and Engineering.
Key Financial Metrics
| Metric (in thousands) | Q1 2003 | Q1 2002 |
|---|---|---|
| Total Revenues | $34,815 | $30,612 |
| Operating Income | $4,089 | $3,902 |
| Net Income | $2,469 | $1,919 |
| Diluted EPS | $0.32 | $0.26 |
| Cash and Equivalents | $21,404 | $7,055 |
| Long-term Obligations | $140 | $167 |
| Operating Cash Flow | ($625) | ($965) |
Margins: Operating margin was approximately 11.7% for Q1 2003. The effective tax rate was 43.5% for the quarter.
Material Changes vs. Prior Period
- Revenue Growth: Revenues increased 13.7% ($4.2 million) year-over-year. Growth was driven by both segments, with the Environmental and Health segment contributing $2.3 million (partially due to the Novigen Sciences acquisition) and the Other Scientific and Engineering segment contributing $1.9 million.
- Profitability: Net income increased 28.7% to $2.469 million. This was aided by a lower effective tax rate (43.5% vs. 52.2% in Q1 2002), as the prior year included a $350,000 deferred tax asset write-off.
- Expenses: Compensation expenses rose 11.5% due to salary increases, higher health insurance costs, and the Novigen acquisition. However, compensation as a percentage of revenue decreased to 59.2% from 60.4%.
- Cash Flow: Net cash used in operating activities improved to ($625,000) from ($965,000) in the prior year, primarily due to higher net income and the absence of the prior year's tax write-off.
Guidance, Outlook, and Risks
Management Commentary: Management attributes revenue growth to increased billable hours, higher billing rates, and the integration of Novigen Sciences. The company continues to expand technical practices into new regions, leading to increased occupancy and relocation costs.
Liquidity: The company maintains a revolving reducing mortgage note with $24.5 million available and $0 outstanding. Management believes existing funds and operating cash will meet needs for the next 12 months, though future acquisitions may require additional capital.
Risks and Contingencies:
- Absence of Backlog: Backlog is small and not a reliable indicator of future revenue due to the nature of client-requested services.
- Customer Concentration: Significant revenue is derived from the transportation industry and government sector; loss of a large client could materially impact results.
- Key Personnel: Success depends on attracting and retaining highly qualified technical staff in a competitive market.
- Economic Sensitivity: Demand is cyclical and subject to general economic conditions.
Investor Verification Checklist
- Novigen Integration: Verify the sustained contribution of the Novigen Sciences acquisition to the Environmental and Health segment revenue and operating income.
- Days Sales Outstanding (DSO): Monitor DSO, which was 102 days in Q1 2003 (improved from 114 days in Q1 2002), to ensure collection efficiency remains stable.
- Stock-Based Compensation: Review pro forma net income under the fair value method (SFAS 123), which would reduce reported net income to $1.937 million for the quarter.
- Fixed-Price Contracts: Assess the company's exposure to cost overruns on fixed-price engagements, as revenue recognition relies on estimates of total labor hours.
- Related Party Transactions: Note the $24,000 software licensing expense paid to a company owned by the husband of a former Novigen president.